Effect of Omega-3 fatty acid supplementation on markers of platelet and endothelial function in patients with peripheral arterial disease

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objective
Omega-3 fatty acids have been shown to reduce platelet and endothelial activation in patients with or at risk of cardiac disease. We aimed to determine if Omega-3 fatty acid supplementation in addition to best medical therapy can reduce the increased platelet and endothelial activity that is present in patients with intermittent claudication.

Methods
One hundred and fifty patients who were receiving aspirin and statin therapy were recruited into a randomised cross-over double blind study involving 6 week supplementation with OMACOR fish oil (850–882 mg eicosapentaenoic and docosahexaenoic acid) versus placebo. A 12 week washout period occurred between treatments. Patients with diabetes were excluded. For each outcome a random effects model was fitted in which treatment and period were fixed effects and patients were random effects.

Results
Omega-3 supplementation had no effect on the primary outcome measure von Willebrand factor. Similarly Omega-3 supplementation resulted in no change in unstimulated or stimulated P-selectin expression and fibrinogen binding, or platelet aggregation (ultegra point of care). Pulse wave velocity was also unchanged. High-sensitivity C-reactive protein, s-ICAM and IL-6 were also unchanged.

Conclusion
Supplementation with Omega-3 fatty acids had no affect on platelet and endothelial activation or markers of inflammation in patients with peripheral arterial disease.
Original languageEnglish
Pages (from-to)514-520
Number of pages7
JournalAtherosclerosis
Volume221
Issue number2
Early online date13 Jan 2012
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Peripheral Arterial Disease
Omega-3 Fatty Acids
Blood Platelets
Platelet Activation
Point-of-Care Systems
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Intermittent Claudication
Pulse Wave Analysis
P-Selectin
Eicosapentaenoic Acid
Docosahexaenoic Acids
Fish Oils
von Willebrand Factor
Therapeutics
Platelet Aggregation
Double-Blind Method
C-Reactive Protein
Fibrinogen
Aspirin
Heart Diseases

Keywords

  • Von-Willebrand-Factor
  • omega-3
  • Platelet function
  • pulse wave velocity
  • intermittent claudication

Cite this

@article{ac9e812e16834839b30470672f94b581,
title = "Effect of Omega-3 fatty acid supplementation on markers of platelet and endothelial function in patients with peripheral arterial disease",
abstract = "ObjectiveOmega-3 fatty acids have been shown to reduce platelet and endothelial activation in patients with or at risk of cardiac disease. We aimed to determine if Omega-3 fatty acid supplementation in addition to best medical therapy can reduce the increased platelet and endothelial activity that is present in patients with intermittent claudication.MethodsOne hundred and fifty patients who were receiving aspirin and statin therapy were recruited into a randomised cross-over double blind study involving 6 week supplementation with OMACOR fish oil (850–882 mg eicosapentaenoic and docosahexaenoic acid) versus placebo. A 12 week washout period occurred between treatments. Patients with diabetes were excluded. For each outcome a random effects model was fitted in which treatment and period were fixed effects and patients were random effects.ResultsOmega-3 supplementation had no effect on the primary outcome measure von Willebrand factor. Similarly Omega-3 supplementation resulted in no change in unstimulated or stimulated P-selectin expression and fibrinogen binding, or platelet aggregation (ultegra point of care). Pulse wave velocity was also unchanged. High-sensitivity C-reactive protein, s-ICAM and IL-6 were also unchanged.ConclusionSupplementation with Omega-3 fatty acids had no affect on platelet and endothelial activation or markers of inflammation in patients with peripheral arterial disease.",
keywords = "Von-Willebrand-Factor, omega-3, Platelet function, pulse wave velocity, intermittent claudication",
author = "Ian Mackay and Isobel Ford and Frank Thies and Shona Fielding and Paul Bachoo and Julie Brittenden",
year = "2012",
month = "4",
doi = "10.1016/j.atherosclerosis.2011.12.041",
language = "English",
volume = "221",
pages = "514--520",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "ELSEVIER IRELAND LTD",
number = "2",

}

TY - JOUR

T1 - Effect of Omega-3 fatty acid supplementation on markers of platelet and endothelial function in patients with peripheral arterial disease

AU - Mackay, Ian

AU - Ford, Isobel

AU - Thies, Frank

AU - Fielding, Shona

AU - Bachoo, Paul

AU - Brittenden, Julie

PY - 2012/4

Y1 - 2012/4

N2 - ObjectiveOmega-3 fatty acids have been shown to reduce platelet and endothelial activation in patients with or at risk of cardiac disease. We aimed to determine if Omega-3 fatty acid supplementation in addition to best medical therapy can reduce the increased platelet and endothelial activity that is present in patients with intermittent claudication.MethodsOne hundred and fifty patients who were receiving aspirin and statin therapy were recruited into a randomised cross-over double blind study involving 6 week supplementation with OMACOR fish oil (850–882 mg eicosapentaenoic and docosahexaenoic acid) versus placebo. A 12 week washout period occurred between treatments. Patients with diabetes were excluded. For each outcome a random effects model was fitted in which treatment and period were fixed effects and patients were random effects.ResultsOmega-3 supplementation had no effect on the primary outcome measure von Willebrand factor. Similarly Omega-3 supplementation resulted in no change in unstimulated or stimulated P-selectin expression and fibrinogen binding, or platelet aggregation (ultegra point of care). Pulse wave velocity was also unchanged. High-sensitivity C-reactive protein, s-ICAM and IL-6 were also unchanged.ConclusionSupplementation with Omega-3 fatty acids had no affect on platelet and endothelial activation or markers of inflammation in patients with peripheral arterial disease.

AB - ObjectiveOmega-3 fatty acids have been shown to reduce platelet and endothelial activation in patients with or at risk of cardiac disease. We aimed to determine if Omega-3 fatty acid supplementation in addition to best medical therapy can reduce the increased platelet and endothelial activity that is present in patients with intermittent claudication.MethodsOne hundred and fifty patients who were receiving aspirin and statin therapy were recruited into a randomised cross-over double blind study involving 6 week supplementation with OMACOR fish oil (850–882 mg eicosapentaenoic and docosahexaenoic acid) versus placebo. A 12 week washout period occurred between treatments. Patients with diabetes were excluded. For each outcome a random effects model was fitted in which treatment and period were fixed effects and patients were random effects.ResultsOmega-3 supplementation had no effect on the primary outcome measure von Willebrand factor. Similarly Omega-3 supplementation resulted in no change in unstimulated or stimulated P-selectin expression and fibrinogen binding, or platelet aggregation (ultegra point of care). Pulse wave velocity was also unchanged. High-sensitivity C-reactive protein, s-ICAM and IL-6 were also unchanged.ConclusionSupplementation with Omega-3 fatty acids had no affect on platelet and endothelial activation or markers of inflammation in patients with peripheral arterial disease.

KW - Von-Willebrand-Factor

KW - omega-3

KW - Platelet function

KW - pulse wave velocity

KW - intermittent claudication

U2 - 10.1016/j.atherosclerosis.2011.12.041

DO - 10.1016/j.atherosclerosis.2011.12.041

M3 - Article

VL - 221

SP - 514

EP - 520

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -